This article is more than 5 years old. Information may no longer be current.

QLT reports increased sales for Visudyne

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER — Sales of QLT’s drug for photodynamic therapy in age-related macular degeneration topped $100 million during the second quarter of this year, according to a press release from the company.

Visudyne (verteporfin for injection, Novartis/QLT) posted sales of $109.3 million for the quarter, the company said, an increase of 23% from sales during the second quarter of 2003. U.S. sales of Visudyne were $52.1 million for the quarter, an increase of 15% over U.S. sales in the second quarter of 2003. Sales for the rest of the world increased 30% in 2004 from 2003, QLT said in the release.

QLT developed Visudyne and shares in its marketing with Novartis Ophthalmics.